삼일제약 Stock: price and insider trades · South Korea
1 insider bought €10k of shares over the last 90 days, the latest by 용환삼, filed 19 Oct 2026.
삼일제약: what insiders have been doing
Every trade that managers of 삼일제약 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 1 November 2026, brought 13 filings signed by 8 insiders.
The record shows 10 purchases on the open market worth €39k, made by 7 insiders, against 2 sales by 1 insider. The totals do not cover 9 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 4 senior executives and 2 chief executives. Biggest ticket of the year: €31k, bought by 허승범 and made public on 27 March 2026 (0.037% of market cap).
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 13 filings here. Since 2021, the database holds 41 purchases and 18 sales by insiders of the company.
In the case of 2 purchases, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The latest purchase is recent: it was published 20 days ago, on 19 October 2026. Between a trade and the moment it shows up on DART (FSS), the median delay is 1 day. The shorter that gap, the sooner other investors can see what insiders have done.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySale+1 other insider
Since the insiders bought
- +7.9%Entry ₩7,090 · Close 30 Oct 2026 ₩7,650
- +7.9%Entry ₩7,090 · Close 30 Oct 2026 ₩7,650
- -16.0%Entry ₩9,110 · Close 30 Oct 2026 ₩7,650
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 1,846 sharesShareKRXDART:20261019000357Canonical exit: 17 Jan 2027 (T+90)
- Other0DART
- Other0DART
- 1,000 sharesShareKRXDART:20260701000110Canonical exit: 29 Sept 2026 (T+90)
- 2,000 sharesShareKRXDART:20260611000666Canonical exit: 9 Sept 2026 (T+90)
- 1,000 sharesShareKRXDART:20260605000358Canonical exit: 3 Sept 2026 (T+90)
- 1,000 shares@ ₩7,490.000.0052% mcap100.0% of flowShareKRXDART:20260601000269Canonical exit: 30 Aug 2026 (T+90)
- 1,000 shares@ ₩7,340.000.0051% mcap100.0% of flowShareKRXDART:20260601000695Canonical exit: 30 Aug 2026 (T+90)
- 10,000 sharesShareKRXDART:20260522000139Canonical exit: 20 Aug 2026 (T+90)
- 200,000 sharesShareKRXDART:20260506000757Canonical exit: 29 Jul 2026 (T+90)
- 20,998 sharesKRXDART:20260423000702
- 5,206 shares@ ₩10,259.000.037% mcap100.0% of flowShareKRXDART:20260327001170Canonical exit: 25 Jun 2026 (T+90)
- ●Executives0DART
- 25,836 sharesKRXDART:20260122000477
- 2,344 sharesShareKRXDART:20260114000094Canonical exit: 14 Apr 2026 (T+90)
- 18,089 sharesShareKRXDART:20250410002661Canonical exit: 9 Jul 2025 (T+90)
- 29,555 sharesKRXDART:20241220000688
- 5,005 sharesShareKRXDART:20241220000619Canonical exit: 20 Mar 2025 (T+90)
- 848,607 sharesKRXDART:20240405002781
- 290,430 sharesKRXDART:20240117000333
- 29,555 sharesKRXDART:20230904000280
- ShareKRXDART:20230710000028Canonical exit: 8 Oct 2023 (T+90)
- ShareKRXDART:20230710000032Canonical exit: 8 Oct 2023 (T+90)
- 29,555 sharesKRXDART:20230621000397
- ShareKRXDART:20230621000389Canonical exit: 17 Sept 2023 (T+90)
25 of 67 declarations
About 삼일제약
삼일제약 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the research, development, and marketing of pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
